Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

October 4, 2018October 4, 2018

FDA Approves Fycompa for Treatment of Focal Seizures in Children Ages 4 and Older

News

The U.S. Food and Drug Administration has approved Fycompa (perampanel) — alone or as an add-on — for the treatment of focal seizures, which affect only one part of the ... Read more

November 7, 2018November 7, 2018

Epidiolex Now Available in the U.S. for Lennox-Gastaut and Dravet Patients 2 and Older

News

Epidiolex (cannabidiol) oral solution is now available in the United States as a treatment for seizures in patients age 2 or older who have Lennox-Gastaut syndrome or Dravet syndrome. Epidiolex is developed ... Read more

November 1, 2018November 1, 2018

Stiripentol Reduces Seizure and Resolves Status Epilepticus, Small Study Reports

News

Treatment with stiripentol reduces seizures and can resolve epileptic episodes, retrospective analysis of a small study in Turkish Dravet syndrome children suggests. The study, “Efficacy of Stiripentol and the Clinical Outcome ... Read more

October 16, 2018October 16, 2018

Fenfluramine May Help Reduce Seizures in Dravet Syndrome, Review Study Reports

News

Fenfluramine, originally developed as an appetite suppressant, shows potential as an anti-epileptic therapy to reduce the seizure rate in Dravet syndrome patients, a review study suggests. The study, “Individualized ... Read more

September 25, 2018September 25, 2018

Supernus Acquires Biscayne, Takes Over BIS-001ER Clinical Program for Dravet Syndrome

News

Supernus Pharmaceuticals now holds the worldwide rights — except in certain markets in Asia — to develop the investigational therapy BIS-001ER, renamed SPN-817, for Dravet syndrome, after a merger ... Read more

August 23, 2018August 23, 2018

FDA Approves Diacomit as Add-On Therapy for Dravet Syndrome

News

The U.S. Food and Drug Administration (FDA) has approved Biocodex’s Diacomit (stiripentol) as an add-on therapy for seizures associated with Dravet syndrome in patients 2 years and older who are undergoing treatment with ... Read more

August 17, 2018August 19, 2018

Dravet Study Links Early Use of Sodium Channel Blockers, Worse Cognitive Function

Just Published, News

Long-term use of sodium channel blockers in the first five years of disease has been linked to poorer cognitive function in Dravet syndrome patients. The study, “Influence of contraindicated ... Read more

July 31, 2018July 31, 2018

Ketogenic Diet Reduces Seizures, Improves Cognitive Function, Small Study Finds

News

The ketogenic diet, which is high in fats and low in carbs, helped reduce the frequency of seizures and improve cognitive function in children with Dravet syndrome who are ... Read more

June 19, 2018June 19, 2018

Dravet Syndrome with Parkinsonian Features Linked to Specific Gene Mutations in Case Report

News

Mutations in a specific gene could be behind adult Dravet syndrome with motor features of Parkinson’s disease, according to case report. The study, “The adult motor phenotype of Dravet ... Read more

March 6, 2018March 6, 2018

Stiripentol Combined With Other Antiepileptic Therapies Has Long-term Effectiveness, Study Says

News

Stiripentol combined with two other antiepileptic medicines seems to be an effective strategy to improve long-term seizure frequency in Dravet syndrome patients. The study that contains that finding, “Stiripentol ... Read more

Pin It on Pinterest